Breaking News Instant updates and real-time market news.

TTEK

Tetra Tech

$157.53 /

+1.47 (+0.94%)

16:39
02/01/23
02/01
16:39
02/01/23
16:39

Tetra Tech raises FY23 EPS view to $4.90-$5.05, consensus $4.92

Raises FY23 revenue view to $3.0B-$3.15B, consensus $3.0B. Prior FY23 guidance was for EPS at $4.70-$4.90 and revenue at $2.9B-$3.1B.

  • 02

    Feb

  • 28

    Feb

OTHER BREAKING NEWS FROM THE FLY

Upgrade
SunPower upgraded to Neutral from Sell at Goldman Sachs » 04:33
03/30/23
03/30
04:33
03/30/23
04:33
SPWR

SunPower

$13.05 /

+0.845 (+6.92%)

Goldman Sachs upgraded…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SPWR SunPower
$13.05 /

+0.845 (+6.92%)

SPWR SunPower
$13.05 /

+0.845 (+6.92%)

03/09/23 Citi
SunPower initiated with a Neutral at Citi
03/02/23 Scotiabank
SunPower initiated with a Sector Perform at Scotiabank
02/17/23 Deutsche Bank
SunPower price target lowered to $15 from $21 at Deutsche Bank
02/16/23 JPMorgan
SunPower price target lowered to $18 from $19 at JPMorgan
SPWR SunPower
$13.05 /

+0.845 (+6.92%)

SPWR SunPower
$13.05 /

+0.845 (+6.92%)

SPWR SunPower
$13.05 /

+0.845 (+6.92%)

SPWR SunPower
$13.05 /

+0.845 (+6.92%)

Upgrade
Fluence Energy upgraded to Buy from Neutral at Goldman Sachs » 04:31
03/30/23
03/30
04:31
03/30/23
04:31
FLNC

Fluence Energy

$16.24 /

+0.4 (+2.53%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
FLNC Fluence Energy
$16.24 /

+0.4 (+2.53%)

FLNC Fluence Energy
$16.24 /

+0.4 (+2.53%)

03/06/23 Guggenheim
Guggenheim downgrades Energy Vault to Neutral on battery storage 'distraction'
02/10/23 Canaccord
Fluence Energy price target raised to $31 from $25 at Canaccord
02/10/23 JPMorgan
Fluence Energy downgraded to Neutral from Overweight at JPMorgan
12/14/22 Canaccord
Fluence Energy price target raised to $25 from $20 at Canaccord
FLNC Fluence Energy
$16.24 /

+0.4 (+2.53%)

FLNC Fluence Energy
$16.24 /

+0.4 (+2.53%)

Downgrade
Loop Energy downgraded to Sector Perform from Outperform at National Bank » 04:28
03/30/23
03/30
04:28
03/30/23
04:28
LPENF

Loop Energy

/

+

National Bank analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LPENF Loop Energy
/

+

01/17/23 National Bank
Loop Energy price target lowered to C$2.50 from C$5 at National Bank
12/16/22 Canaccord
Loop Energy downgraded to Hold from Speculative Buy at Canaccord
11/07/22 Canaccord
Loop Energy price target lowered to C$2.75 from C$3.75 at Canaccord
11/04/22 Raymond James
Loop Energy price target lowered to C$2.50 from C$3 at Raymond James
General news
Market Update: » 03:00
03/30/23
03/30
03:00
03/30/23
03:00
$ECON

Economic Data

/

+

Market Update: The stock…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

Syndicate
Avadel Pharmaceuticals 10M share Spot Secondary priced at $8.50 » 21:35
03/29/23
03/29
21:35
03/29/23
21:35
AVDL

Avadel Pharmaceuticals

$8.90 /

-0.27 (-2.94%)

The deal priced below…

The deal priced below last closing price of $8.89. Jefferies is acting as lead book running manager for the offering.

ShowHide Related Items >><<
AVDL Avadel Pharmaceuticals
$8.90 /

-0.27 (-2.94%)

AVDL Avadel Pharmaceuticals
$8.90 /

-0.27 (-2.94%)

03/23/23 H.C. Wainwright
Avadel Pharmaceuticals price target raised to $14 from $13 at H.C. Wainwright
11/30/22 Jefferies
Avadel upgraded to Buy at Jefferies after survey of sleep doctors
11/30/22 Jefferies
Avadel Pharmaceuticals upgraded to Buy from Hold at Jefferies
11/21/22 Needham
Avadel Pharmaceuticals price target raised to $9 from $8 at Needham
AVDL Avadel Pharmaceuticals
$8.90 /

-0.27 (-2.94%)

  • 30
    Mar
AVDL Avadel Pharmaceuticals
$8.90 /

-0.27 (-2.94%)

AVDL Avadel Pharmaceuticals
$8.90 /

-0.27 (-2.94%)

AVDL Avadel Pharmaceuticals
$8.90 /

-0.27 (-2.94%)

General news
Treasury Market Summary: » 20:25
03/29/23
03/29
20:25
03/29/23
20:25
$ECON

Economic Data

/

+

Treasury Market Summary:…

Treasury Market Summary: Wall Street opened firmly and extended gains amid reduced stress over the banking system and increased optimism that the fallout has been contained. Calm is returning to the markets now that no additional reports of bank problems have been reported. Earnings beats from Micron and Lululemon were upbeat surprises too. The NASDAQ surged 1.72% to, while the S&P 500 climbed 1.42%, with the Dow up 1.00%. The break over the 4014 on the S&P 500, the 50-day moving average, helped propel the markets higher too with the index finishing at 4027.8. Treasuries had a modest bid most of the day even as risk appetite jumped. The 2-year Treasury ended at 4.09% and the 10-year was at 3.56%. The DXY dollar index firmed to 102.786 but lost some steam to end the day at 102.642. The buck rallied against JPY to 132.86 as the yen lost some of its haven demand.

ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

Hot Stocks
Cathie Wood's ARK Investment bought 224.2K shares of SomaLogic today  20:03
03/29/23
03/29
20:03
03/29/23
20:03
SLGC

SomaLogic

$2.29 /

-0.06 (-2.56%)

 
ShowHide Related Items >><<
SLGC SomaLogic
$2.29 /

-0.06 (-2.56%)

SLGC SomaLogic
$2.29 /

-0.06 (-2.56%)

03/29/23 Canaccord
SomaLogic price target lowered to $5 from $6 at Canaccord
03/29/23 TD Cowen
SomaLogic price target lowered to $7 from $8 at TD Cowen
03/29/23 Stifel
SomaLogic price target lowered to $7 from $8 at Stifel
08/16/22 TD Cowen
SomaLogic price target lowered to $9 from $11 at Cowen
SLGC SomaLogic
$2.29 /

-0.06 (-2.56%)

SLGC SomaLogic
$2.29 /

-0.06 (-2.56%)

SLGC SomaLogic
$2.29 /

-0.06 (-2.56%)

Hot Stocks
Adtran announces retirement of CFO » 20:02
03/29/23
03/29
20:02
03/29/23
20:02
ADTN

Adtran

$15.64 /

+0.11 (+0.71%)

Adtran "announced…

Adtran "announced that after 39 years in the telecommunications industry, ADTRAN Holdings' CFO, Mike Foliano, will retire from the Company effective on June 28, 2023. The Company also announced the appointment of Uli Dopfer as the Company's new CFO, effective May 1, 2023. Uli Dopfer previously served as CFO of ADVA Optical Networking for the past 8 years."

ShowHide Related Items >><<
ADTN Adtran
$15.64 /

+0.11 (+0.71%)

ADTN Adtran
$15.64 /

+0.11 (+0.71%)

02/22/23 TD Cowen
Adtran price target lowered to $31 from $34 at Cowen
09/26/22 Loop Capital
Adtran upgraded to Buy from Hold at Loop Capital
09/26/22 Loop Capital
Adtran upgraded to Buy from Hold at Loop Capital
09/13/22 WestPark Capital
Adtran initiated with a Hold at WestPark Capital
ADTN Adtran
$15.64 /

+0.11 (+0.71%)

ADTN Adtran
$15.64 /

+0.11 (+0.71%)

Hot Stocks
Faraday Future starts production of FF 91 Futurist Alliance » 20:01
03/29/23
03/29
20:01
03/29/23
20:01
FFIE

Faraday Future

/

+

Faraday Future announced…

Faraday Future announced the start of production of the all-new Ultimate Intelligent TechLuxury FF 91 Futurist Alliance at its FF ieFactory located in Hanford, California. The FF 91 Futurist is the Company's first production vehicle and flagship model that is expected to be offered in both the U.S. and China markets.

ShowHide Related Items >><<
FFIE Faraday Future
/

+

FFIE Faraday Future
/

+

08/16/22 Benchmark
Faraday Future downgraded to Speculative Hold from Buy at Benchmark
FFIE Faraday Future
/

+

FFIE Faraday Future
/

+

FFIE Faraday Future
/

+

Recommendations
Netflix update on sharing efforts likely a positive catalyst, says Wells Fargo » 19:39
03/29/23
03/29
19:39
03/29/23
19:39
NFLX

Netflix

$332.24 /

+8.695 (+2.69%)

Wells Fargo keeps an…

Wells Fargo keeps an Overweight rating and $400 price target on Netflix while noting that the company's upcoming commentary on its paid subscriber sharing policy with Q1 results will likely serve as a "positive catalyst". In U.S. and Canada, some accounts will pay the $8/month average revenue per user, while others will drop their sharers with some of those subscribing on their own, but the firm's base case suggest 7M net adds from paid sharing vs. consensus view of 2M net adds in FY23, the analyst tells investors in a research note. Consensus calls for 15M net adds this year, but contribution from Netflix paid sharing efforts alone worldwide could be over 20M in Wells Fargo's base case, and the firm believes that "significant upward revisions look likely" for the company.

ShowHide Related Items >><<
NFLX Netflix
$332.24 /

+8.695 (+2.69%)

NFLX Netflix
$332.24 /

+8.695 (+2.69%)

03/20/23 JPMorgan
Netflix Paid Sharing launches bring near-term 'noise,' says JPMorgan
03/16/23 Citi
Netflix price target raised to $400 from $395 at Citi
03/15/23 Oppenheimer
Netflix share pullback brings buying opportunity, says Oppenheimer
02/23/23 Guggenheim
Netflix price cuts highlight focus on maximizing revenue, says Guggenheim
NFLX Netflix
$332.24 /

+8.695 (+2.69%)

NFLX Netflix
$332.24 /

+8.695 (+2.69%)

NFLX Netflix
$332.24 /

+8.695 (+2.69%)

NFLX Netflix
$332.24 /

+8.695 (+2.69%)

Hot Stocks
Charles Schwab director buys $267.3K in common stock » 19:27
03/29/23
03/29
19:27
03/29/23
19:27
SCHW

Charles Schwab

$55.22 /

+1.36 (+2.53%)

In a regulatory filing,…

In a regulatory filing, Charles Schwab disclosed that its director Marianne Brown bought bought 5.0K shares of common stock on March 28th in a total transaction size of $267.3K.

ShowHide Related Items >><<
SCHW Charles Schwab
$55.22 /

+1.36 (+2.53%)

SCHW Charles Schwab
$55.22 /

+1.36 (+2.53%)

03/29/23 Citi
Charles Schwab price target lowered to $65 from $75 at Citi
03/22/23 Barclays
Charles Schwab price target lowered to $61 from $79 at Barclays
03/15/23 Credit Suisse
Charles Schwab upgraded to Outperform from Neutral at Credit Suisse
03/14/23 JPMorgan
Schwab funding concerns 'significantly de-risked,' says JPMorgan
SCHW Charles Schwab
$55.22 /

+1.36 (+2.53%)

  • 10
    Mar
  • 02
    Aug
SCHW Charles Schwab
$55.22 /

+1.36 (+2.53%)

SCHW Charles Schwab
$55.22 /

+1.36 (+2.53%)

SCHW Charles Schwab
$55.22 /

+1.36 (+2.53%)

Hot Stocks
Paychex CEO: Our value proposition continues to resonate in the market » 18:46
03/29/23
03/29
18:46
03/29/23
18:46
PAYX

Paychex

$116.03 /

+7.07 (+6.49%)

In an interview on…

In an interview on CNBC's Mad Money, John Gibson said the market continues to view Paychex as a stable adviser in difficult times. He noted that the company had no cash or investments in any of the banks impacted by the SVB crisis. He urged policy makers to step in to ensure there is more access to capital.

ShowHide Related Items >><<
PAYX Paychex
$116.03 /

+7.07 (+6.49%)

PAYX Paychex
$116.03 /

+7.07 (+6.49%)

03/13/23 Barclays
Paychex price target lowered to $105 from $110 at Barclays
01/17/23 Barclays
Paychex downgraded to Underweight from Equal Weight at Barclays
01/03/23 Deutsche Bank
Paychex price target lowered to $116 from $123 at Deutsche Bank
12/27/22 Evercore ISI
Paychex price target lowered to $114 from $117 at Evercore ISI
PAYX Paychex
$116.03 /

+7.07 (+6.49%)

PAYX Paychex
$116.03 /

+7.07 (+6.49%)

PAYX Paychex
$116.03 /

+7.07 (+6.49%)

PAYX Paychex
$116.03 /

+7.07 (+6.49%)

Hot Stocks
Wolverine World Wide proposes U.K. workforce reduction » 18:38
03/29/23
03/29
18:38
03/29/23
18:38
WWW

Wolverine World Wide

$16.12 /

+0.06 (+0.37%)

The company states:…

The company states: 'Wolverine World Wide announced actions intended to improve operating performance, fuel global growth, and enable future investments into Sweaty Betty, a global premium women's activewear brand acquired in August 2021. Sweaty Betty will now report into Wolverine Worldwide's London-based International Group, which is responsible for the Company's operations outside the United States. This move will more closely align Sweaty Betty with Wolverine's global centers of excellence. As part of this transition, several opportunities have been identified to better align Sweaty Betty's cost structure to Wolverine's other brands and enable future investments. These include consolidating London office space, securing savings through Wolverine's new Profit Improvement Office, and proposing a UK workforce reduction. The expected impact of these actions is reflected in the Company's 2023 guidance."

ShowHide Related Items >><<
WWW Wolverine World Wide
$16.12 /

+0.06 (+0.37%)

WWW Wolverine World Wide
$16.12 /

+0.06 (+0.37%)

03/13/23
Seaport cites five reasons for upgrade of Wolverine World Wide
03/13/23
Wolverine World Wide upgraded to Buy from Neutral at Seaport Global
01/16/23 Williams Trading
Wolverine World Wide upgraded to Buy from Hold at Williams Trading
01/04/23 Piper Sandler
Wolverine World Wide downgraded to Neutral from Overweight at Piper Sandler
WWW Wolverine World Wide
$16.12 /

+0.06 (+0.37%)

WWW Wolverine World Wide
$16.12 /

+0.06 (+0.37%)

Earnings
Aerovate Therapeutics reports Q4 EPS (61c), consensus (62c) » 18:37
03/29/23
03/29
18:37
03/29/23
18:37
AVTE

Aerovate Therapeutics

$19.29 /

+0.45 (+2.39%)

Cash, cash equivalents…

Cash, cash equivalents and short-term investments totaled $129.2 million as of December 31, 2022, compared to $142.6 million as of September 30, 2022. The decrease was primarily driven by operational costs for the three-month period ended December 31, 2022. The company "expects that cash, cash equivalents and available-for-sale investments will be sufficient to fund our operations into the second half of 2025, based on our current operating plan." CEO Tim Noyes says: "Aerovate had a productive year in 2022 as evidenced by the progress made with our lead pipeline candidate AV-101 and strategic additions to our management team. We believe AV-101, if approved, has the potential to become part of a new standard of care for patients with PAH by directly delivering a novel antiproliferative therapy to the pulmonary vasculature in a way that may offer broad efficacy and a low side effect burden to complement current and future treatment options. With its convenient twice daily dosing and easy-to-use pocket-size inhaler, we are optimistic about the potential of AV-101 to help us deliver on our vision of providing patients with meaningful treatment solutions."

ShowHide Related Items >><<
AVTE Aerovate Therapeutics
$19.29 /

+0.45 (+2.39%)

AVTE Aerovate Therapeutics
$19.29 /

+0.45 (+2.39%)

02/28/23 Guggenheim
Aerovate Therapeutics initiated with Buy, $36 target at Guggenheim
02/28/23 Guggenheim
Aerovate Therapeutics initiated with a Buy at Guggenheim
12/12/22 Wedbush
Aerovate Therapeutics price target raised to $54 from $27 at Wedbush
12/06/22 BTIG
Aerovate upgraded to Buy at BTIG after Gossamer study hits endpoint
Hot Stocks
Calavo Growers CEO buys $1.4M in common stock » 18:35
03/29/23
03/29
18:35
03/29/23
18:35
CVGW

Calavo Growers

$26.91 /

-1.19 (-4.23%)

In a regulatory filing,…

In a regulatory filing, Calavo Growers disclosed that its CEO Lecil Cole bought 50K shares of common stock on March 28th in a total transaction size of $1.4M. Shares of Calavo Growers are up 2% afterhours at $27.45.

ShowHide Related Items >><<
CVGW Calavo Growers
$26.91 /

-1.19 (-4.23%)

CVGW Calavo Growers
$26.91 /

-1.19 (-4.23%)

03/07/23 Lake Street
Calavo Growers price target lowered to $38 from $50 at Lake Street
03/07/23 Stephens
Calavo Growers price target lowered to $35 from $39 at Stephens
12/21/22 Lake Street
Calavo Growers price target lowered to $50 from $60 at Lake Street
09/02/22 Lake Street
Calavo Growers headwind sources in Q3 unlikely to persist, says Lake Street
CVGW Calavo Growers
$26.91 /

-1.19 (-4.23%)

CVGW Calavo Growers
$26.91 /

-1.19 (-4.23%)

Recommendations
Alcoa price target lowered to $47 from $52 at Morgan Stanley » 18:29
03/29/23
03/29
18:29
03/29/23
18:29
AA

Alcoa

$40.95 /

+0.42 (+1.04%)

Morgan Stanley analyst…

Morgan Stanley analyst Carlos De Alba lowered the firm's price target on Alcoa to $47 from $52 and keeps an Equal Weight rating on the shares as part of a broader research note on Americas Metals & Mining. While the firm is constructive over the long term on decarbonization and electrification trends that support demand for metals and challenging conditions to develop new supply, it prefers to "take chips off the table" as mining equities share prices are more adequately reflecting the China reopening, the analyst tells investors in a research note. Morgan Stanley adds that it prefers to see evidence that Alcoa's recent operational setbacks in the bauxite and alumina businesses are resolved.

ShowHide Related Items >><<
AA Alcoa
$40.95 /

+0.42 (+1.04%)

AA Alcoa
$40.95 /

+0.42 (+1.04%)

03/14/23 BMO Capital
Alcoa transferred with a Market Perform rating at BMO Capital
02/21/23 Citi
Alcoa upgraded to Buy at Citi on 'bullish' aluminum view
02/21/23 Citi
Alcoa upgraded to Buy from Neutral at Citi
02/01/23 UBS
Alcoa price target raised to $50 from $44 at UBS
AA Alcoa
$40.95 /

+0.42 (+1.04%)

AA Alcoa
$40.95 /

+0.42 (+1.04%)

AA Alcoa
$40.95 /

+0.42 (+1.04%)

AA Alcoa
$40.95 /

+0.42 (+1.04%)

Recommendations
Teck Resources price target lowered to $42 from $44 at Morgan Stanley » 18:27
03/29/23
03/29
18:27
03/29/23
18:27
TECK

Teck Resources

$35.60 /

+0.345 (+0.98%)

Morgan Stanley analyst…

Morgan Stanley analyst Carlos De Alba lowered the firm's price target on Teck Resources to $42 from $44 but keeps an Overweight rating on the shares as part of a broader research note on Americas Metals & Mining, also stating that the stock remains the firm's Top Pick in the space. While Morgan Stanley is constructive over the long term on decarbonization and electrification trends that support demand for metals and challenging conditions to develop new supply, it prefers to "take chips off the table" as mining equities share prices are more adequately reflecting the China reopening, the analyst tells investors in a research note. The analyst adds that Teck offers growing exposure to copper and long-term potential expansion in volumes and EBITDA, stating that it sees Teck's asset base and free cash flow rising in coming years post QB2 completion that may result in higher dividends ahead.

ShowHide Related Items >><<
TECK Teck Resources
$35.60 /

+0.345 (+0.98%)

TECK Teck Resources
$35.60 /

+0.345 (+0.98%)

03/14/23 Scotiabank
Teck Resources price target raised to C$75 from C$70 at Scotiabank
03/02/23 Deutsche Bank
Teck Resources price target raised to $46 from $42 at Deutsche Bank
02/23/23 TD Securities
Teck Resources price target raised to C$71 from C$67 at TD Securities
02/22/23 RBC Capital
Teck Resources price target raised to C$72 from C$64 at RBC Capital
TECK Teck Resources
$35.60 /

+0.345 (+0.98%)

TECK Teck Resources
$35.60 /

+0.345 (+0.98%)

TECK Teck Resources
$35.60 /

+0.345 (+0.98%)

TECK Teck Resources
$35.60 /

+0.345 (+0.98%)

Hot Stocks
Macy's CEO: We've been working on the CEO transition plan for two years » 18:23
03/29/23
03/29
18:23
03/29/23
18:23
M

Macy's

$17.32 /

+0.05 (+0.29%)

In an interview on…

In an interview on CNBC's Mad Money, Jeff Gennette said Macy's is "ready for me to hand it off." He's "very excited" about Tony Spring's leadership and noted that he's "set to hit the ground running." Gennette added that he's "very committed to ensuring that it's a smooth transition."

ShowHide Related Items >><<
M Macy's
$17.32 /

+0.05 (+0.29%)

M Macy's
$17.32 /

+0.05 (+0.29%)

03/29/23
Gordon Haskett downgrades Macy's on moderating foot traffic trends
03/29/23
Macy's downgraded to Hold from Accumulate at Gordon Haskett
03/03/23 TD Cowen
Macy's price target raised to $29 from $27 at TD Cowen
02/23/23 Citi
Macy's price target raised to $23 from $22 at Citi
M Macy's
$17.32 /

+0.05 (+0.29%)

M Macy's
$17.32 /

+0.05 (+0.29%)

M Macy's
$17.32 /

+0.05 (+0.29%)

M Macy's
$17.32 /

+0.05 (+0.29%)

Hot Stocks
Kohl's CEO buys $2.02M in common stock » 18:17
03/29/23
03/29
18:17
03/29/23
18:17
KSS

Kohl's

$22.06 /

+0.29 (+1.33%)

In a regulatory filing,…

In a regulatory filing, Kohl's disclosed that its CEO Thomas Kingsbury bought 92.5K shares of common stock on March 29th in a total transaction size of $2.02M.

ShowHide Related Items >><<
KSS Kohl's
$22.06 /

+0.29 (+1.33%)

KSS Kohl's
$22.06 /

+0.29 (+1.33%)

03/29/23 UBS
Kohl's price target lowered to $16 from $18 at UBS
03/02/23 Deutsche Bank
Kohl's price target lowered to $31 from $34 at Deutsche Bank
03/02/23 Citi
Kohl's price target lowered to $26 from $29 at Citi
03/02/23 Morgan Stanley
Kohl's assumed with an Underweight at Morgan Stanley
KSS Kohl's
$22.06 /

+0.29 (+1.33%)

KSS Kohl's
$22.06 /

+0.29 (+1.33%)

KSS Kohl's
$22.06 /

+0.29 (+1.33%)

KSS Kohl's
$22.06 /

+0.29 (+1.33%)

On The Fly
Fly Intel: After-Hours Movers » 18:14
03/29/23
03/29
18:14
03/29/23
18:14
CXM

Sprinklr

$10.90 /

+0.25 (+2.35%)

, BCEL

Atreca

$1.30 /

+0.01 (+0.78%)

, ACLX

Arcellx

$31.06 /

+0.805 (+2.66%)

, PACW

PacWest Bancorp

$9.87 /

+0.475 (+5.06%)

, NKTR

Nektar

/

+

, CR

Crane

$111.37 /

+4.285 (+4.00%)

, SMTC

Semtech

$32.10 /

+0.97 (+3.12%)

, CNXC

Concentrix

$121.77 /

+2.06 (+1.72%)

, BEEM

Beam Global

$16.71 /

+0.675 (+4.21%)

, RH

RH

$245.86 /

+4.74 (+1.97%)

, VRNT

Verint

$37.43 /

+0.85 (+2.32%)

, FUL

H.B. Fuller

$68.40 /

+0.59 (+0.87%)

, VKTX

Viking Therapeutics

$15.93 /

+0.52 (+3.37%)

, BTU

Peabody Energy

$25.20 /

-0.41 (-1.60%)

Check out this evening's…

ShowHide Related Items >><<
VRNT Verint
$37.43 /

+0.85 (+2.32%)

VKTX Viking Therapeutics
$15.93 /

+0.52 (+3.37%)

SMTC Semtech
$32.10 /

+0.97 (+3.12%)

RH RH
$245.86 /

+4.74 (+1.97%)

PACW PacWest Bancorp
$9.87 /

+0.475 (+5.06%)

NKTR Nektar
/

+

FUL H.B. Fuller
$68.40 /

+0.59 (+0.87%)

CXM Sprinklr
$10.90 /

+0.25 (+2.35%)

CR Crane
$111.37 /

+4.285 (+4.00%)

CNXC Concentrix
$121.77 /

+2.06 (+1.72%)

BTU Peabody Energy
$25.20 /

-0.41 (-1.60%)

BEEM Beam Global
$16.71 /

+0.675 (+4.21%)

BCEL Atreca
$1.30 /

+0.01 (+0.78%)

ACLX Arcellx
$31.06 /

+0.805 (+2.66%)

CXM Sprinklr
$10.90 /

+0.25 (+2.35%)

02/15/23 Barclays
Sprinklr price target raised to $13 from $10 at Barclays
02/03/23 Morgan Stanley
Sprout, Sprinklr pacts minimize impact of Twitter decision, says Morgan Stanley
01/24/23 Cantor Fitzgerald
Sprinklr initiated with an Overweight at Cantor Fitzgerald
01/12/23 Oppenheimer
Sprinklr downgraded to Perform from Outperform at Oppenheimer
BCEL Atreca
$1.30 /

+0.01 (+0.78%)

01/20/23 Brookline
Atreca assumed with a Buy at Brookline
01/04/23 EF Hutton
Atreca initiated with a Buy at EF Hutton
11/15/22 Wedbush
Atreca price target lowered to $4 from $12 at Wedbush
05/19/22 Baird
Atreca price target lowered to $9 from $12 at Baird
ACLX Arcellx
$31.06 /

+0.805 (+2.66%)

03/13/23 Stifel
Arcellx initiated with a Buy at Stifel
02/22/23 Roth MKM
Immix Biopharma initiated with a Buy at Roth MKM
02/13/23 H.C. Wainwright
Arcellx initiated with a Buy at H.C. Wainwright
12/13/22 BofA
Arcellx resumed with a Buy at BofA
PACW PacWest Bancorp
$9.87 /

+0.475 (+5.06%)

03/23/23 Truist
PacWest Bancorp price target lowered to $13 from $29 at Truist
03/23/23 Piper Sandler
PacWest 'can make it to the other side,' says Piper Sandler
03/22/23 RBC Capital
PacWest provides detailed update on deposit balances, says RBC Capital
03/20/23 Piper Sandler
Piper confident PacWest can make it through liquidity crunch
NKTR Nektar
/

+

02/24/23 SVB Securities
Nektar price target lowered to $3 from $5 at SVB Securities
02/24/23 Jefferies
Nektar downgraded to Underperform from Hold at Jefferies
11/29/22 Guggenheim
Guggenheim starts Medicenna Therapeutics with a Buy on MDNA11 potential
08/08/22 JPMorgan
Nektar downgraded to Underweight from Neutral at JPMorgan
CR Crane
$111.37 /

+4.285 (+4.00%)

03/29/23 DA Davidson
Crane, Crane NXT worth owning post-separation, says DA Davidson
03/24/23 UBS
Crane downgraded to Neutral into NXT separation at UBS
03/24/23 UBS
Crane downgraded to Neutral from Buy at UBS
01/25/23 DA Davidson
Crane price target raised to $140 from $130 at DA Davidson
SMTC Semtech
$32.10 /

+0.97 (+3.12%)

03/22/23 B. Riley
B. Riley upgrades Semtech to Buy into 'period of estimate stability'
03/21/23 B. Riley
Semtech upgraded to Buy from Neutral at B. Riley
12/01/22 TD Cowen
Semtech price target lowered to $33 from $43 at Cowen
12/01/22 Benchmark
Semtech price target lowered to $45 from $65 at Benchmark
CNXC Concentrix
$121.77 /

+2.06 (+1.72%)

09/30/22 Barrington
Concentrix price target lowered to $174 from $183 at Barrington
07/05/22 Barrington
Concentrix price target lowered to $183 from $202 at Barrington
BEEM Beam Global
$16.71 /

+0.675 (+4.21%)

02/13/23 Northland
Beam Global initiated with an Outperform at Northland
11/14/22 H.C. Wainwright
Beam Global upgraded to Buy from Neutral at H.C. Wainwright
08/15/22 Maxim
Beam Global price target lowered to $40 from $50 at Maxim
06/17/22 B. Riley
Beam Global initiated with Buy, $23 target at B. Riley
RH RH
$245.86 /

+4.74 (+1.97%)

03/27/23 Wedbush
RH price target lowered to $245 from $335 at Wedbush
03/06/23 Jefferies
RH cut to Hold at Jefferies with luxury housing market 'struggling to stabilize'
03/06/23 Jefferies
RH downgraded to Hold from Buy at Jefferies
02/07/23 Barclays
Barclays sees a 'reset' in U.S. retail but 'not a recession yet'
VRNT Verint
$37.43 /

+0.85 (+2.32%)

01/05/23 Jefferies
Verint downgraded to Hold from Buy at Jefferies
12/08/22 RBC Capital
Verint price target lowered to $48 from $58 at RBC Capital
12/08/22 Wedbush
Verint price target lowered to $45 from $56 at Wedbush
12/08/22 TD Cowen
Verint price target lowered to $50 from $75 at Cowen
FUL H.B. Fuller
$68.40 /

+0.59 (+0.87%)

02/03/23 Citi
H.B. Fuller upgraded to Buy from Neutral at Citi
01/23/23 Citi
H.B. Fuller price target raised to $72 from $65 at Citi
01/20/23 Deutsche Bank
H.B. Fuller price target raised to $78 from $72 at Deutsche Bank
01/20/23 Baird
H.B. Fuller price target lowered to $80 from $85 at Baird
VKTX Viking Therapeutics
$15.93 /

+0.52 (+3.37%)

03/29/23 Truist
Viking Therapeutics price target raised to $32 from $28 at Truist
03/29/23 Roth MKM
Viking Therapeutics price target raised to $19 from $15 at Roth MKM
03/29/23 Maxim
Viking Therapeutics price target raised to $25 from $15 at Maxim
03/29/23 Raymond James
Viking Therapeutics price target raised to $35 from $12 at Raymond James
BTU Peabody Energy
$25.20 /

-0.41 (-1.60%)

03/14/23 BMO Capital
Peabody Energy transferred with a Market Perform rating at BMO Capital
01/17/23 B. Riley
Peabody Energy price target raised to $39 from $37 at B. Riley
11/18/22 BMO Capital
Peabody Energy price target raised to $31 from $28 at BMO Capital
10/11/22 B. Riley
Peabody Energy price target raised to $31 from $28 at B. Riley
VRNT Verint
$37.43 /

+0.85 (+2.32%)

VKTX Viking Therapeutics
$15.93 /

+0.52 (+3.37%)

SMTC Semtech
$32.10 /

+0.97 (+3.12%)

RH RH
$245.86 /

+4.74 (+1.97%)

PACW PacWest Bancorp
$9.87 /

+0.475 (+5.06%)

NKTR Nektar
/

+

FUL H.B. Fuller
$68.40 /

+0.59 (+0.87%)

CXM Sprinklr
$10.90 /

+0.25 (+2.35%)

CR Crane
$111.37 /

+4.285 (+4.00%)

CNXC Concentrix
$121.77 /

+2.06 (+1.72%)

BTU Peabody Energy
$25.20 /

-0.41 (-1.60%)

BEEM Beam Global
$16.71 /

+0.675 (+4.21%)

BCEL Atreca
$1.30 /

+0.01 (+0.78%)

ACLX Arcellx
$31.06 /

+0.805 (+2.66%)

  • 30
    Mar
  • 17
    Jun
VKTX Viking Therapeutics
$15.93 /

+0.52 (+3.37%)

PACW PacWest Bancorp
$9.87 /

+0.475 (+5.06%)

BTU Peabody Energy
$25.20 /

-0.41 (-1.60%)

VRNT Verint
$37.43 /

+0.85 (+2.32%)

VKTX Viking Therapeutics
$15.93 /

+0.52 (+3.37%)

SMTC Semtech
$32.10 /

+0.97 (+3.12%)

RH RH
$245.86 /

+4.74 (+1.97%)

PACW PacWest Bancorp
$9.87 /

+0.475 (+5.06%)

NKTR Nektar
/

+

FUL H.B. Fuller
$68.40 /

+0.59 (+0.87%)

CR Crane
$111.37 /

+4.285 (+4.00%)

CNXC Concentrix
$121.77 /

+2.06 (+1.72%)

BTU Peabody Energy
$25.20 /

-0.41 (-1.60%)

BEEM Beam Global
$16.71 /

+0.675 (+4.21%)

ACLX Arcellx
$31.06 /

+0.805 (+2.66%)

VKTX Viking Therapeutics
$15.93 /

+0.52 (+3.37%)

RH RH
$245.86 /

+4.74 (+1.97%)

PACW PacWest Bancorp
$9.87 /

+0.475 (+5.06%)

BTU Peabody Energy
$25.20 /

-0.41 (-1.60%)

Hot Stocks
Volta stockholders approve merger transaction with Shell USA » 18:12
03/29/23
03/29
18:12
03/29/23
18:12
VLTA

Volta

/

+

, SHEL

Shell

$57.11 /

+0.94 (+1.67%)

Volta (VLTA) stockholders…

Volta (VLTA) stockholders approved the proposal to adopt the agreement and plan of merger dated January 17 under which Shell USA, a subsidiary of Shell (SHEL), has agreed to acquire Volta through a merger of a direct, wholly-owned subsidiary of Shell USA with and into Volta, with Volta continuing as the surviving corporation in the merger. The transaction is expected to close on or about March 31 subject to customary closing conditions. Following the closing of the transaction, shares of Volta common stock will be delisted from trading on the NYSE and de-registered. Volta stockholders will be entitled to receive $0.86 in cash, without interest and net of withholding taxes, for each share of Volta Class A common stock upon the completion of the merger.

ShowHide Related Items >><<
VLTA Volta
/

+

SHEL Shell
$57.11 /

+0.94 (+1.67%)

VLTA Volta
/

+

11/16/22 DA Davidson
Volta price target lowered to $1 from $2 at DA Davidson
11/16/22 Barclays
Volta price target lowered to 50c from $2 at Barclays
11/15/22 Raymond James
Volta downgraded to Market Perform from Outperform at Raymond James
08/09/22 Roth MKM
Volta downgraded to Neutral from Buy at Roth Capital
SHEL Shell
$57.11 /

+0.94 (+1.67%)

03/21/23 Morgan Stanley
Shell price target lowered to 2,405 GBp from 2,625 GBp at Morgan Stanley
02/28/23 AlphaValue/Baader
Shell upgraded to Add from Reduce at AlphaValue/Baader
02/26/23 Goldman Sachs
Shell upgraded to Buy from Neutral at Goldman Sachs
02/24/23 JPMorgan
Shell price target raised to 3,000 GBp from 2,950 GBp at JPMorgan
VLTA Volta
/

+

SHEL Shell
$57.11 /

+0.94 (+1.67%)

SHEL Shell
$57.11 /

+0.94 (+1.67%)

VLTA Volta
/

+

SHEL Shell
$57.11 /

+0.94 (+1.67%)

VLTA Volta
/

+

SHEL Shell
$57.11 /

+0.94 (+1.67%)

Downgrade
Nexa Resources downgraded to Underweight from Overweight at Morgan Stanley » 18:08
03/29/23
03/29
18:08
03/29/23
18:08
NEXA

Nexa Resources

$6.17 /

+0.14 (+2.32%)

Morgan Stanley downgraded…

Morgan Stanley downgraded Nexa Resources to Underweight from Overweight with a price target of $5.60, down from $6.00, as part of a broader research note on Americas Metals & Mining. While the firm remains constructive over the long term on decarbonization/electrification trends that support demand for metals and challenging conditions to develop new supply, it prefers to "take chips off the table" as mining equities share prices are more adequately reflecting the China reopening. The timing and magnitude of the company's operational turnaround were "overestimated", Morgan Stanley adds, noting that it is now cutting its 2023 and 2024 EBITDA estimates by 40% and 5% respectively after incorporating the company's latest guidance.

ShowHide Related Items >><<
NEXA Nexa Resources
$6.17 /

+0.14 (+2.32%)

NEXA Nexa Resources
$6.17 /

+0.14 (+2.32%)

09/16/22 Morgan Stanley
Nexa Resources upgraded to Overweight from Equal Weight at Morgan Stanley
Downgrade
Southern Copper downgraded to Equal Weight from Overweight at Morgan Stanley » 18:06
03/29/23
03/29
18:06
03/29/23
18:06
SCCO

Southern Copper

$75.74 /

+1.93 (+2.61%)

Morgan Stanley analyst…

Morgan Stanley analyst Carlos De Alba downgraded Southern Copper to Equal Weight from Overweight with an unchanged $70 price target as part of a broader research note on Americas Metals & Mining. While the firm remains constructive over the long term on decarbonization/electrification trends that support demand for metals and challenging conditions to develop new supply, it prefers to "take chips off the table" as mining equities share prices are more adequately reflecting the China reopening. Southern Copper has outperformed its copper peers over the last three, six, and 12 months, but its risk-reward is now more balanced with the stock more adequately reflecting the company's strong cash generation and consistent returns to shareholder, the analyst tells investors in a research note.

ShowHide Related Items >><<
SCCO Southern Copper
$75.74 /

+1.93 (+2.61%)

03/14/23 Scotiabank
Freeport-McMoRan upgraded to Outperform from Sector Perform at Scotiabank
01/30/23 Barclays
Southern Copper price target raised to $56 from $55 at Barclays
01/11/23 Citi
Southern Copper price target raised to $60 from $40 at Citi
01/11/23 Wolfe Research
Wolfe upgrades Southern Copper to Peer Perform on falling costs
SCCO Southern Copper
$75.74 /

+1.93 (+2.61%)

SCCO Southern Copper
$75.74 /

+1.93 (+2.61%)

Hot Stocks
Alpine Acquisition unable to complete Two Bit Circus transaction » 17:59
03/29/23
03/29
17:59
03/29/23
17:59
REVE

Alpine Acquisition

$10.00 /

+0.44 (+4.60%)

The company states:…

The company states: "As previously disclosed, on May 18, 2022, Alpine Acquisition Corporation entered into an Agreement and Plan of Merger, with AAC Merger Sub Inc., a Delaware corporation and wholly-owned subsidiary of Alpine, and Two Bit Circus, Inc. Pursuant to the Merger Agreement, Merger Sub was to merge with and into TBC, with TBC surviving the merger as a wholly-owned subsidiary of Alpine. Concurrently with the execution of the Merger Agreement, Alpine entered into a Purchase and Sale Agreement with Pool IV Finance LLC, Pool IV TRS LLC and PHF II Stamford LLC pursuant to which Alpine was to purchase the Hilton Stamford Hotel & Executive Meeting Center and the Crowne Plaza Denver Airport Convention Center Hotel simultaneously with the closing of the Merger. Alpine has determined that it will be unable to consummate the transactions contemplated by the Business Combination Agreements within the required time period and therefore has determined to cancel its special meeting in lieu of an annual meeting of stockholders called to approve such transactions. Alpine will now commence the process of liquidating its assets in accordance with its amended and restated certificate of incorporation. Alpine's warrants will expire worthless."

ShowHide Related Items >><<
REVE Alpine Acquisition
$10.00 /

+0.44 (+4.60%)

Earnings
Heritage Cannabis reports Q1 EPS 0c vs 1c last year » 17:50
03/29/23
03/29
17:50
03/29/23
17:50
HERTF

Heritage Cannabis

/

+

The Company reported…

The Company reported gross revenue of $9,446,995 for the three months ended January 31, a decrease of $149,146 compared to the gross revenue of $9,596,141 for the three months ended January 31. The decrease in gross revenue was primarily due to negative pricing movements in the period by the provincial boards which impacted the results by over $125,000. "In a traditionally slow period, we are very pleased to have achieved gross margin growth - evidence our continued focus to lower our operational costs has been effective. Even with a number of our achievements expecting to positively impact our operations in the coming months, such as our Thrifty brand launch and U.S. investments, we are continuing to remain focused on cost management while improving our market penetration in our core markets", said David Schwede, CEO of Heritage. "While this past quarter we saw provincial pricing that negatively impacted our results, we feel the majority of this reset is now behind us and we can focus on continued growth by leading in market innovation, focusing on growing our entire portfolio of in-demand products. With our U.S. strategy ramping up and early indications showing positive results ahead of expectations, we are well positioned to see an up-trend in the business in 2023."

ShowHide Related Items >><<
HERTF Heritage Cannabis
/

+

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.